Skip to content

ALA-CPM

Diagnostic laparoscopy with 5-aminolevulinic acid for peritoneal metastasis from colorectal cancer

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031200038
Enrollment
20
Registered
2020-05-28
Start date
2020-05-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

peritoneal metastasis from colorectal cancer peritoneal metastasis from colorectal cancer, 5-ALA

Interventions

3-4 hours before the operation, 1.5 g (20 mg / kg) of araglio granules was dissolved in 50 ml of water and orally administered. Under general anesthesia and insufflation of carbon dioxide gas, the ins

Sponsors

Gohda Yoshimasa
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patient diagnosed or suspiciously as peritoneal metastasis from colorectal cancer 2) Patient aged from 20 to 75 years 3) Patient with ECOG performance status of 0 or 1

Exclusion criteria

Exclusion criteria: 1) Porphyria. Patients with a history of sun or photosensitivity. 2) Patients with a history of hypersensitivity to porphyrins. 3) Patients taking drugs that may induce photosensitivity. 4) In addition, patients whose physician judged that participation in this study was inappropriate.

Design outcomes

Primary

MeasureTime frame
ALA-PDD increases the accuracy of peritoneal metastasis (Comparison of sensitivity between white light and blue light)

Secondary

MeasureTime frame
Safety

Contacts

Public ContactGohda Yoshimasa

National Center for Global health and Medicine

ygohda@hosp.ncgm.go.jp+81-332027181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026